LLY — Recent News Coverage
All news mentioning LLY in ESEN's AI-graded feed
News stories with LLY as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on LLY. See /coverage/LLY for the 30-day aggregate.
MANILATIMES.NET
·
2026-11-17
NEUTRAL
BULLISH
CORR0.58
Cancer Vaccines Clinical Trial Pipeline Boom as 200+ Companies are in the Race for Better Treatments | DelveInsight
$BNTX
$MRNA
$LLY
◈ ESEN AI
An analysis of the cancer vaccine clinical trial landscape reveals a significant inflection point in oncology R&D, with 200+ companies now competing in this therapeutic category. This proliferation signals growing confi…
SEEKINGALPHA
·
2026-11-17
HIGH
BULLISH
CORR0.72
Rythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVR
$RYTM
$LLY
◈ ESEN AI
Rythm Pharmaceuticals (RYTM) is responding to market chatter regarding an unsolicited acquisition proposal from Eli Lilly (LLY) valued at $150 per share, reportedly inclusive of a contingent value right (CVR). This repr…
CNBC
·
2026-11-16
NEUTRAL
NEUTRAL
CORR0.42
Eli Lilly makes a deal outside obesity. Plus, another word of caution on Nvidia
$LLY
$NVDA
◈ ESEN AI
Eli Lilly has expanded its strategic portfolio beyond the obesity market through a new deal, signaling management's confidence in diversifying revenue streams away from the crowded GLP-1 receptor agonist space. This mov…
SEEKINGALPHA
·
2026-11-16
HIGH
BULLISH
CORR0.72
Eli Lilly in up to $1.5B deal to acquire Calytrix Bio
$LLY
◈ ESEN AI
Eli Lilly (LLY) announced a strategic acquisition of Calytrix Bio for up to $1.5 billion, signaling aggressive expansion in its pipeline and therapeutic capabilities. This deal represents a material capital deployment d…
FORTUNE.COM
·
2026-08-12
NEUTRAL
BEARISH
CORR0.45
Lilly escalates its fight against black market weight-loss shots
$LLY
◈ ESEN AI
Eli Lilly (LLY) faces mounting pressure from counterfeit weight-loss medications flooding black markets, threatening both revenue integrity and brand reputation. The proliferation of knockoff versions of the company's b…
THEHINDUBUSINESSLINE.COM
·
2026-08-12
NEUTRAL
NEUTRAL
CORR0.42
Eli Lilly escalates fight against black market weight-loss medicines
$LLY
$NVO
◈ ESEN AI
Eli Lilly is escalating enforcement against counterfeit and illegally distributed retatrutide products in the US market. The company plans to file lawsuits against businesses engaged in unauthorized sales while simultan…
FINANCE.YAHOO.COM
·
2026-08-11
HIGH
BEARISH
CORR0.42
Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?
$LLY
$NVO
◈ ESEN AI
NVO has escalated competitive tensions by filing a federal lawsuit against LLY over GLP-1 obesity drug marketing practices, alleging false advertising and unfair competition. This litigation marks a shift from pure comm…
INSIDERMONKEY.COM
·
2026-08-10
NEUTRAL
NEUTRAL
CORR0.55
Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America’s New Drug Manufacturing Policies?
$LLY
$NVO
◈ ESEN AI
Eli Lilly (LLY) and Novo Nordisk (NVO) face a strategic inflection point as U.S. drug manufacturing policy shifts. The article frames a comparative positioning analysis rather than a market-moving catalyst, examining ho…
INSIDERMONKEY.COM
·
2026-08-10
NEUTRAL
NEUTRAL
CORR0.55
Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?
$LLY
$NVO
◈ ESEN AI
The GLP-1 competitive landscape has shifted from pure clinical differentiation toward manufacturing and supply-chain capabilities as a critical differentiator. Eli Lilly (LLY) and Novo Nordisk (NVO) are both investing h…
INSIDERMONKEY.COM
·
2026-08-10
NEUTRAL
BULLISH
CORR0.55
Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY
$JNJ
$LLY
$AMGN
$BMY
◈ ESEN AI
The article reflects a thematic rotation narrative where portfolio managers seek innovation exposure outside the technology sector after an extended tech rally. Large-cap pharmaceutical companies—particularly JNJ, LLY, …
FINANCE.YAHOO.COM
·
2026-08-08
LOW
NEUTRAL
CORR0.42
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?
$LLY
$VKTX
◈ ESEN AI
This article presents a comparative investment analysis of two GLP-1 drug developers—Eli Lilly (LLY) and Viking Therapeutics (VKTX)—within the rapidly expanding weight-loss and metabolic disease treatment market. The fr…
THEHINDUBUSINESSLINE.COM
·
2026-08-08
LOW
NEUTRAL
CORR0.15
What they say on their India plans
$LLY
$BLL
$CMI
$KMB
◈ ESEN AI
This earnings-season roundup captures forward guidance commentary from multinational executives regarding India market strategies. The article aggregates management perspectives rather than presenting a discrete catalys…
MANILATIMES.NET
·
2026-08-07
LOW
NEUTRAL
CORR0.15
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026
$LLY
◈ ESEN AI
Nxera Pharma (TSE: 4565), a biopharmaceutical company with operations spanning Tokyo and Cambridge, has released its Q2 2026 operational and financial results. This represents a routine earnings disclosure with limited …
SEEKINGALPHA.COM
·
2026-08-06
HIGH
BULLISH
CORR0.72
Eli Lilly: Fine Q2 2026 Results, But Alertness Required (NYSE:LLY)
$LLY
◈ ESEN AI
Eli Lilly (LLY) delivered Q2 2026 results that exceeded expectations, driving a 5% stock price appreciation on earnings day. The company's raised revenue guidance signals management confidence in sustained demand and op…
SEEKINGALPHA.COM
·
2026-08-05
NEUTRAL
NEUTRAL
CORR0.32
Eli Lilly and Company (LLY) Q2 2026 Earnings Call Transcript
$LLY
◈ ESEN AI
Eli Lilly (LLY) released its Q2 2026 earnings call transcript, providing management commentary on operational performance and strategic initiatives. As a routine earnings disclosure, this represents standard corporate c…
SEEKINGALPHA.COM
·
2026-08-05
NEUTRAL
NEUTRAL
CORR0.35
Eli Lilly and Company 2026 Q2 - Results - Earnings Call Presentation (NYSE:LLY) 2026-08-05
$LLY
◈ ESEN AI
Eli Lilly (LLY) published its Q2 2026 earnings call presentation on August 5th, providing institutional investors with detailed financial and operational performance metrics. The disclosure represents standard quarterly…
SEEKINGALPHA.COM
·
2026-08-05
HIGH
BULLISH
CORR0.72
Eli Lilly Q2 Earnings Review: Results Mean Higher Ceiling On Stock Price Target
$LLY
◈ ESEN AI
Eli Lilly (LLY) delivered better-than-expected Q2 results and raised full-year 2026 guidance, primarily driven by accelerating demand for its GLP-1 therapeutics portfolio, particularly Mounjaro and Zepbound. This earnin…
CNBC.COM
·
2026-08-05
NEUTRAL
NEUTRAL
CORR0.35
Jim Cramer's top 10 things to watch in the stock market Wednesday
$AMD
$LLY
$NVDA
◈ ESEN AI
AMD and SpaceX are experiencing post-earnings pullbacks, signaling that market participants are reassessing growth trajectories and valuation multiples after reported results. This reflects typical earnings volatility w…
RTTNEWS.COM
·
2026-08-05
HIGH
BULLISH
CORR0.72
Eli Lilly Boosts FY26 Revenue Outlook; Stock Up 5.2% - Update
$LLY
◈ ESEN AI
Eli Lilly (LLY) reported Q2 results with a notable divergence in guidance: while raising full-year 2026 revenue expectations, the company trimmed earnings guidance, signaling a composition shift in profitability drivers…
FINANCE.YAHOO.COM
·
2026-08-04
NEUTRAL
BULLISH
CORR0.72
Eli Lilly Is Up 7% in 2026 and Has Major Catalysts on the Way. Is the Rally Just Getting Started?
$LLY
◈ ESEN AI
Eli Lilly (LLY) has already gained 7% in 2026 and is positioned with multiple forward catalysts that could extend momentum. The article highlights potential 2027 inflection points that may begin pricing in ahead of form…
MANILATIMES.NET
·
2026-08-03
NEUTRAL
NEUTRAL
CORR0.15
Zuellig Pharma Acquires Cialis® (Tadalafil) from Lilly in Singapore
$LLY
◈ ESEN AI
Eli Lilly (LLY) has divested its Cialis® (tadalafil) asset in Singapore to regional distributor Zuellig Pharma, a localized portfolio optimization move within Asia-Pacific markets. This represents a targeted geographic …
FINANCE.YAHOO.COM
·
2026-07-31
NEUTRAL
NEUTRAL
CORR0.42
Novo Nordisk vs Eli Lilly: The Better Buy Before Earnings
$LLY
$NVO
◈ ESEN AI
Novo Nordisk and Eli Lilly face a critical inflection point as both companies navigate the mature GLP-1 receptor agonist market ahead of earnings season. While both firms have established significant market presence in …
FINANCE.YAHOO.COM
·
2026-07-29
NEUTRAL
NEUTRAL
CORR0.42
Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth
$JNJ
$LLY
◈ ESEN AI
Johnson & Johnson and Eli Lilly present a study in contrasting growth trajectories within pharmaceutical and life sciences. While JNJ has maintained steady, predictable revenue expansion reflective of a mature diversifi…
FINANCE.YAHOO.COM
·
2026-07-28
NEUTRAL
BULLISH
CORR0.58
Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs
$LLY
$NVDA
◈ ESEN AI
Eli Lilly's $2.8 billion capital deployment signals management confidence beyond its dominant GLP-1 franchise, which has driven recent outperformance. The specificity of this bet—whether in manufacturing infrastructure,…
INSIDERMONKEY.COM
·
2026-07-25
NEUTRAL
NEUTRAL
CORR0.35
Jim Cramer Wants Novo Nordisk A/S (NYSE:NVO) To Compete With Eli Lilly In The Market & Not The Courts
$NVO
$LLY
◈ ESEN AI
Novo Nordisk (NVO) initiated legal action against Eli Lilly (LLY) in the competitive weight loss pharmaceutical market, drawing commentary from prominent market observers. The lawsuit represents an escalation in rivalry…
FINANCE.YAHOO.COM
·
2026-07-24
NEUTRAL
BEARISH
CORR-0.15
Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors?
$NVO
$LLY
◈ ESEN AI
Novo Nordisk's legal action against Eli Lilly reflects intensifying competitive pressure within the high-growth GLP-1 receptor agonist market. The dispute centers on advertising claims, suggesting both companies are agg…
CNBC
·
2026-07-23
NEUTRAL
BEARISH
CORR-0.35
Wall Street stumbles as oil surges, and Lilly takes a new path on next-gen obesity drug
$LLY
$XLE
◈ ESEN AI
Oil's sharp ascent is pressuring equities broadly as energy costs ripple through production and transportation expenses across the economy. This headwind typically weighs on consumer discretionary spending and margin ex…
MANILATIMES.NET
·
2026-07-23
NEUTRAL
NEUTRAL
CORR0.35
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight
$AMGN
$LLY
$INCY
◈ ESEN AI
The molecular glues therapeutic landscape is experiencing significant competitive expansion, with 80+ emerging pipeline candidates competing for clinical advancement and market share. This represents a fragmented R&D en…
LIVEMINT.COM
·
2026-07-23
HIGH
BULLISH
CORR0.72
Eli Lilly’s next-generation weight-loss shot clears another hurdle
$LLY
$NVO
◈ ESEN AI
Eli Lilly's next-generation weight-loss therapeutic has achieved a critical milestone by demonstrating no increase in overall cardiovascular risk in clinical testing. This data point removes a significant regulatory and…
INSIDERMONKEY.COM
·
2026-07-23
HIGH
BULLISH
CORR0.72
Big Pharma Is Buying Growth. Novartis (NVS) Is Betting on Its Pipeline
$NVS
$LLY
$MRK
$PFE
◈ ESEN AI
Biotech M&A activity has doubled year-over-year, with deal value reaching $216 billion through current 2026 data versus $118 billion in the prior-year period. This acceleration signals heightened strategic consolidation…
MANILATIMES.NET
·
2026-07-21
NEUTRAL
BULLISH
CORR0.58
PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight
$JNJ
$LLY
$INCY
$BNTX
◈ ESEN AI
The report analyzes a competitive landscape of 200+ PD-1 and PD-L1 inhibitor drugs across clinical development and approved therapies, identifying 180+ companies positioned to influence oncology therapeutics. This depth…
CNBC
·
2026-07-21
NEUTRAL
NEUTRAL
CORR0.45
Jim Cramer says he's standing by Eli Lilly after rival's GLP-1 lawsuit. Here's why
$LLY
◈ ESEN AI
Eli Lilly (LLY) remains in focus as high-profile commentary affirms conviction amid competitive GLP-1 pressures. The GLP-1 receptor agonist market has evolved into a contested arena with litigation risk now embedded acr…
FORBES.COM
·
2026-07-20
HIGH
BULLISH
CORR0.72
Big Pharma And Psychedelic Medicine: Eli Lilly’s $3.8 Billion Bet
$LLY
$JNJ
◈ ESEN AI
Eli Lilly's $3.8 billion acquisition of AtaiBeckley represents a watershed moment for institutional capital entering psychedelic medicine. The deal signals that legacy pharma recognizes potential therapeutic value in co…
SEEKINGALPHA.COM
·
2026-07-19
NEUTRAL
NEUTRAL
CORR0.52
Notable healthcare headlines for the week: UnitedHealth, J&J, and Intuitive Surgical in focus
$UNH
$JNJ
$ISRG
$LLY
◈ ESEN AI
UnitedHealth (UNH) guidance elevation signals management confidence in the managed care segment, supporting valuations within the health insurance subsector. Positive earnings typically reflect underlying cost managemen…
SEEKINGALPHA.COM
·
2026-07-17
NEUTRAL
BULLISH
CORR0.58
Novo Nordisk: The Oral Wegovy Promise (NYSE:NVO)
$NVO
$LLY
◈ ESEN AI
Novo Nordisk (NVO) has appreciated 40% since April, driven by investor optimism surrounding the oral formulation of Wegovy, its blockbuster GLP-1 receptor agonist. The shift from injectable to oral delivery represents a…
MANILATIMES.NET
·
2026-07-17
NEUTRAL
BULLISH
CORR0.72
Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 - The Stock Now Trades Above $1,200
$LLY
◈ ESEN AI
Eli Lilly (LLY) has delivered exceptional returns for early investors, with the stock appreciating from $350 in 2020 to above $1,200 currently—a 3.4x gain over roughly four years. The Atlas Healthcare Fund by VST Capita…
ETFTRENDS.COM
·
2026-07-17
NEUTRAL
BULLISH
CORR0.58
Use These ETFs as Health Stocks LLY, UNH, MRK Thrive
$LLY
$UNH
$MRK
◈ ESEN AI
Health care equities demonstrated positive momentum this week, with a focus on large-cap pharmaceutical and managed care operators. The article highlights LLY, UNH, and MRK as beneficiaries of favorable sector tailwinds…
RTTNEWS.COM
·
2026-07-17
HIGH
BULLISH
CORR0.72
Top Biotech Gainers: CDNA Soars On Medicare Policy, ATAI Acquired, ABT Lifts Outlook, APLM On Watch
$CDNA
$ATAI
$ABT
$LLY
◈ ESEN AI
CDNA's rally reflects regulatory clarity on molecular testing reimbursement, a meaningful inflection for diagnostic companies dependent on Medicare coverage decisions. The finalized Local Coverage Determination removes …
VCNEWSDAILY.COM
·
2026-07-16
NEUTRAL
BULLISH
CORR0.35
AdvanCell Closes $315 Million Series D
$LLY
◈ ESEN AI
AdvanCell has successfully closed an oversubscribed and upsized $315 million Series D financing round, signaling strong investor confidence in clinical-stage radiopharmaceutical development. The oversubscription indicat…
SEEKINGALPHA
·
2026-07-16
NEUTRAL
BULLISH
CORR0.58
Eli Lilly deal to buy AtaiBeckley boosts psychedelic stocks
$LLY
$CMPS
$MIND
◈ ESEN AI
Eli Lilly's acquisition of AtaiBeckley signals institutional validation of the psychedelic therapeutic space, historically marginalized from mainstream pharma investment. The deal introduces blue-chip credibility to a s…
SEEKINGALPHA
·
2026-07-16
HIGH
BULLISH
CORR0.72
Psychedelic drugmaker AtaiBeckley shares soar 66% on Eli Lilly buyout talks
$LLY
$ATAI
◈ ESEN AI
ATAI Biotech shares surged 66% on reports of acquisition talks with Eli Lilly, signaling major pharma's aggressive move into the emerging psychedelic therapeutics space. This represents a strategic pivot by LLY to expan…
MANILATIMES.NET
·
2026-07-14
NEUTRAL
BULLISH
CORR0.42
Tuberculosis Clinical Trial Pipeline Shows Potential with Active Contributions from 28+ Key Companies | DelveInsight
$LLY
$NVO
◈ ESEN AI
A comprehensive clinical trial pipeline analysis identifies 30+ tuberculosis therapeutics under development, with 28+ companies actively participating in research and development efforts. This consolidated pipeline revi…
INVESTORIDEAS.COM
·
2026-07-10
HIGH
BULLISH
CORR0.72
Wall Street Lifts Obesity Drug Targets for Eli Lilly and AbbVie as Medicare Coverage Expands
$LLY
$ABBV
◈ ESEN AI
Eli Lilly (LLY) and AbbVie (ABBV) are receiving elevated price targets from Wall Street analysts following expanded Medicare coverage for their obesity medications. The Medicare GLP-1 Bridge program represents a materia…
ETFTRENDS.COM
·
2026-07-08
NEUTRAL
BULLISH
CORR0.58
Strong LLY News Boosts Active Healthcare ETF GDOC
$LLY
$JNJ
◈ ESEN AI
Eli Lilly (LLY) positive developments are providing tailwinds to active healthcare-focused ETF strategies, particularly those with tactical positioning flexibility. The underlying strength in a marquee pharmaceutical na…
ETFTRENDS.COM
·
2026-07-07
NEUTRAL
BULLISH
CORR0.72
Inside THNR: A Leaner Approach to Weight Loss Investing
$LLY
$AZN
$NVO
$REGN
$ABBV
◈ ESEN AI
The THNR ETF represents a thematic investment vehicle focused on the accelerating GLP-1 drug category and weight loss therapeutics market. This specialized fund provides concentrated exposure to LLY, AZN, and NVO, which…
ZACKS.COM
·
2026-07-06
NEUTRAL
NEUTRAL
CORR0.15
Top Stock Reports for Eli Lilly, HSBC & Palantir
$LLY
$HSBC
$PLTR
◈ ESEN AI
This Zacks analyst roundup aggregates equity research across three structurally distinct names: LLY (pharmaceutical/biotech), HSBC (global banking), and PLTR (software/data analytics). The briefing format emphasizes gro…
FINANCE.YAHOO.COM
·
2026-07-06
NEUTRAL
NEUTRAL
CORR0.42
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
$LLY
$TEVA
◈ ESEN AI
Eli Lilly (LLY) and Teva Pharmaceutical (TEVA) represent divergent positioning within the pharma landscape, reflecting structural differences in growth trajectory and valuation. LLY commands a 33x forward earnings multi…
FINANCE.YAHOO.COM
·
2026-07-06
NEUTRAL
BEARISH
CORR0.42
Eli Lilly and Company (LLY) Fell on Regulatory And Pricing Policy Challenges
$LLY
◈ ESEN AI
Eli Lilly (LLY) experienced downward pressure during Q1 2026, primarily driven by regulatory scrutiny and evolving pricing policy constraints. The decline reflects broader market sensitivity to pharmaceutical sector hea…
MANILATIMES.NET
·
2026-07-06
NEUTRAL
BULLISH
CORR0.42
DKSH Enters Strategic Partnership with Lilly in Hong Kong SAR and Macau SAR
$LLY
◈ ESEN AI
DKSH, a leading distribution and supply chain partner in Asia, has formalized a strategic partnership with Eli Lilly (LLY) to expand pharmaceutical distribution across Hong Kong and Macau. This agreement builds on exist…
FINANCE.YAHOO.COM
·
2026-07-04
NEUTRAL
BULLISH
CORR0.72
Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly
$LLY
$JNJ
◈ ESEN AI
Eli Lilly (LLY) and Johnson & Johnson (JNJ) delivered Q1 2026 results that underscore divergent but complementary strategies within large-cap healthcare. Both companies raised forward guidance, signaling confidence in n…
EXPLORE OTHER FILTERS